100
Participants
Start Date
April 30, 2025
Primary Completion Date
June 30, 2028
Study Completion Date
June 30, 2028
Sacituzumab Govitecan-hziy (SG)
Administered intravenously
RECRUITING
St. Vincent's Hospital - Kinghorn Cancer Center, Darlinghurst
RECRUITING
John Flynn Private Hospital, Tugun
RECRUITING
Sunshine Coast University Private Hospital, Birtinya
RECRUITING
Virginia Oncology Associates, Norfolk
RECRUITING
Winship Cancer Institute - Emory University, Atlanta
RECRUITING
SCRI Oncology Partners, Nashville
RECRUITING
Tennessee Oncology, PLLC, Nashville
RECRUITING
West Cancer Centre, Germantown
RECRUITING
Siteman Cancer Center, St Louis
RECRUITING
Texas Oncology - DFW, Dallas
RECRUITING
Los Angeles Cancer Network (LACN) - Good Sam, Los Angeles
RECRUITING
Seoul National University Hospital, Seoul
NOT_YET_RECRUITING
Severance Hospital, Yonsei University Health System, Seoul
RECRUITING
Asan Medical Center, Seoul
RECRUITING
Samsung Medical Center, Seoul
Lead Sponsor
Gilead Sciences
INDUSTRY